On Tuesday, Johnson & Johnson said that its experimental HIV vaccine failed to give adequate protection to young women in Sub-Saharan Africa who are at high risk of infection.
The failure of a mid-stage experiment underlines the difficulties of vaccine development, particularly for HIV, or human immunodeficiency virus, for which no vaccines have been approved.
“HIV is a unique and complex virus that has long posed unprecedented challenges for vaccine development because of its ability to attack, hijack and evade the human immune system,” Paul Stoffels, J&J’s chief scientific officer, said in a statement.
The study testing the vaccine included the participation of 2,600 women across five Southern African countries, where women and girls accounted for over 60% of all new HIV infections last year.
The trial of the vaccine, which is based on the adenovirus design which J&J’s COVID-19 vaccine also uses, was supported by the U.S. the National Institute of Allergy and Infectious Diseases and the Bill & Melinda Gates Foundation.
The study will not continue, based on the data, J&J said. Participants in the study will be informed about the results and told whether they received a placebo or the vaccine.
J&J said it is studying the safety and efficacy of a different composition of the vaccine regimen among men who have sex with men and transgender persons.
Antibiotic use has surged globally, leading to a rise in antibiotic resistance, especially concerning in…
Choking is a leading cause of injury and death in young children, particularly those under…
Hard Water (Khara Pani) Leading To Hair Fall Hard water is rich in minerals and…
Discover how the rise in high blood pressure during pregnancy is impacting maternal and fetal…
"Discover the transformative power of six delicious homemade drinks that can help you naturally melt…
"Transform your weight loss routine with these eight delicious fat-flushing drinks that not only hydrate…